Stem cells and cell-based therapies for cerebral palsy: a call for rigor

Area of Science:

• Neuroscience
• Regenerative Medicine
• Pediatric Neurology

Background:

• Perinatal brain injury (PBI) causes multifaceted neural damage, leading to cerebral palsy (CP) in infants.
• Developing neural networks are vulnerable to cell damage and signaling perturbations.
• Cell-based therapies present a potential avenue for repairing neural components during critical developmental windows.

Purpose of the Study:

• To review current knowledge and identify key questions in cell-based therapies for infants at risk of CP.
• To guide pediatric specialists in counseling families about emerging treatment options.
• To enhance rigor and ensure the safety of this vulnerable patient population.

Main Methods:

• Review of existing literature on cell-based therapies for neurological disorders.
• Analysis of challenges specific to treating PBI in infants.
• Examination of lessons learned from cell-based therapies in mature central nervous system disorders.

Main Results:

• Identified critical knowledge gaps regarding optimal patient selection, treatment goals, delivery strategies (timing, dose, location, type), and efficacy tracking.
• Highlighted challenges unique to PBI and cell-based interventions in infants.
• Reviewed strategies to increase rigor in the field.

Conclusions:

• Cell-based therapies hold significant promise for infants at risk of CP, but require further research to address critical knowledge gaps.
• Optimizing treatment strategies and ensuring patient safety are paramount for successful clinical translation.
• A rigorous approach is essential to advance the field and benefit vulnerable infants.